Home   Help   Citation   About

Citation: Zhou et al., Nature Commun. 2019 10(1):1523.

7 technologies, 29 tissues and cell lines, 22 studies, 390 COVID gene lists.

Welcome to Coronaspace!

Use the "Browse All" tab to download COVID lists.

To analyze your gene list against selected COVID lists, paste yours into the "User's Gene list" box, click "Similarity Search" under the "Recommendation" tab, add a few reference lists to the "Reference Lists to Compare", then click on "Metascape Analysis" button for a rich "Analysis Report Page" (limit: up to 8 reference lists).

"Search" and "GO Heatmap" tabs provide additional means to build up COVID reference lists with "Use Selected" or "Append Selected".

To perform Metascape "Custom Analysis" or analyze more than 8 lists, click on "Download Reference Lists" then use the Metascape web site.

User's Gene List

try example!
Reference Lists to Compare

First paste in your gene list, then click "search" to compare your list against all COVID lists. The most statistically overlapped reference lists are provided, which are the best candidates for "Metascape Analysis".

Top 20Top 100Top GO Level

Hint: to select multiple check boxes, press SHIFT key.

Hint: to select multiple check boxes, press SHIFT key.

1. Davis et al. Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies bioRxiv pre-print
Interactome for CoV-1/CoV-2 NSP2 and NSP4.

 IsOMICS Interactome (AP-MS),  SampleType in vitro,  CellType HEK293T,  VirusStrain SARS-CoV-2 isolate Wuhan-Hu-1,  Timepoints 40h,  Perturbations ,  HasCompleteData ,  GeneListSource .

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined100       94 (94%)
COVID079 Interactome_Davis_HEK-293T_40h_NSP2 19 Interactome HEK-293T NSP2 40h 4 (21%) 16 (84%)
COVID080 Interactome_Davis_HEK-293T_40h_NSP4 85 Interactome HEK-293T NSP4 40h 4 (5%) 82 (96%)

2. Zhang et al. Single-cell landscape of immunological responses in patients with COVID-19 Nature Immunology peer reviewed
scRNA-seq comparison of PBMCs in severe, moderate, convalescent, and healthy donors.

 IsOMICS scRNA-seq, Single-cell T cell receptor (TCR) and B cell receptor (BCR) sequencing,  SampleType patient and healthy samples,  CellType ,  VirusStrain ,  Timepoints n/a,  Perturbations ,  HasCompleteData Yes,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined418       387 (93%)
COVID351 RNA_Zhang_Monocytes_severe-only_Up 47 scRNA-seq Monocytes Severe SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 severe patients (n=4) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. 14 (30%) 45 (96%)
COVID352 RNA_Zhang_Monocytes_moderate-only_Up 26 scRNA-seq Monocytes Moderate SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. 15 (58%) 22 (85%)
COVID353 RNA_Zhang_Monocytes_severe-and-moderate_Up 127 scRNA-seq Monocytes Severe and moderate SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 severe (n=4) and moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value in severe patients. 87 (69%) 121 (95%)
COVID354 RNA_Zhang_NK-cells_severe-only_Up 45 scRNA-seq NK cells Severe SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 severe patients (n=4) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. 40 (89%) 41 (91%)
COVID355 RNA_Zhang_NK-cells_moderate-only_Up 10 scRNA-seq NK cells Moderate SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. 10 (100%) 8 (80%)
COVID356 RNA_Zhang_NK-cells_severe-and-moderate_Up 95 scRNA-seq NK cells Severe and moderate SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 severe (n=4) and moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value in severe patients. 95 (100%) 87 (92%)
COVID357 RNA_Zhang_T-cells_severe-only_Up 79 scRNA-seq T cells Severe SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 severe patients (n=4) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. 41 (52%) 70 (89%)
COVID358 RNA_Zhang_T-cells_moderate-only_Up 18 scRNA-seq T cells Moderate SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. 10 (56%) 14 (78%)
COVID359 RNA_Zhang_T-cells_severe-and-moderate_Up 139 scRNA-seq T cells Severe and moderate SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 severe (n=4) and moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value in severe patients. 113 (81%) 132 (95%)
COVID360 RNA_Zhang_B-cells_severe-only_Up 81 scRNA-seq B cells Severe SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 severe patients (n=4) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. 21 (26%) 78 (96%)
COVID361 RNA_Zhang_B-cells_moderate-only_Up 28 scRNA-seq B cells Moderate SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value. 17 (61%) 27 (96%)
COVID362 RNA_Zhang_B-cells_severe-and-moderate_Up 74 scRNA-seq B cells Severe and moderate SARS-CoV-2 Healthy donors Post admission SARS-CoV-2 severe (n=4) and moderate patients (n=7) vs. healthy donors (n=5). Singificance defined by p-value < 0.01 and Log2FC >= 0.5. Features sorted by p-value in severe patients. 63 (85%) 68 (92%)

3. Klann et al. Growth factor receptor signaling inhibition prevents SARSCoV-2 replication Molecular Cell peer reviewed
Phosphoproteomics and proteomics study of CoV-2 infected Caco-2 cells.

 IsOMICS Phosphoproteome and Proteome,  SampleType in vitro,  CellType Caco-2,  VirusStrain SARS-CoV-2,  Timepoints 24h,  Perturbations ,  HasCompleteData ,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined904       795 (88%)
COVID234 Phosphoproteome_Klann_Caco-2_24h_Down 300 Phosphoproteome Caco-2 SARS-CoV-2 Mock 24h Significance defined by Abs(Log2FC)>1 and Adj P<0.05. Features sorted by pvalue. 63 (21%) 266 (89%)
COVID235 Phosphoproteome_Klann_Caco-2_24h_Up 300 Phosphoproteome Caco-2 SARS-CoV-2 Mock 24h Significance defined by Abs(Log2FC)>1 and Adj P<0.05. Features sorted by pvalue. 45 (15%) 262 (87%)
COVID236 Proteome_Klann_Caco-2_24h_Down 300 Proteome Caco-2 SARS-CoV-2 Mock 24h Significance defined by Abs(Log2FC)>0.5 and Adj P<0.05. Features sorted by pvalue. 32 (11%) 268 (89%)
COVID237 Proteome_Klann_Caco-2_24h_Up 76 Proteome Caco-2 SARS-CoV-2 Mock 24h Significance defined by Abs(Log2FC)>0.5 and Adj P<0.05. Features sorted by pvalue. 3 (4%) 67 (88%)

4. Riva et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing Nature peer reviewed
Processed RNAseq data from mock-infected and SARS-CoV-2 infected Vero E6 cells (MOI=0.3) collected 24 hpi (“RNAseq_Vero E6”).

 IsOMICS RNA-seq,  SampleType in vitro,  CellType Vero-E6 cells,  VirusStrain SARS-CoV-2 USA-WA1/2020,  Timepoints 24h,  Perturbations ,  HasCompleteData ,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined380       333 (88%)
COVID242 RNA_Riva_Vero-E6_24h_Down 80 RNA-seq Vero-E6 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>1 and Adj P<0.01. Features sorted by pvalue. 0 (0%) 57 (71%)
COVID243 RNA_Riva_Vero-E6_24h_Up 300 RNA-seq Vero-E6 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>1 and Adj P<0.01. Features sorted by pvalue. 0 (0%) 276 (92%)

5. Bojkova et al. SARS-CoV-2 infected host cell proteomics reveal potential therapy targets Nature peer reviewed (pre-proof)
Proteome and Translatome of SARS-CoV-2 infected CaCo-2 cells.
Extracted lists from supplement tables 1 & 2 (FC > 1.5, pvalue<0.05)
 IsOMICS Proteomics (abundance),  SampleType in vitro,  CellType CaCo-2,  VirusStrain SARS-CoV-2, clinical isolates, not specified,  Timepoints 2, 6, 10, 24 h,  Perturbations ,  HasCompleteData yes,  GeneListSource .

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined453       387 (85%)
COVID218 Proteome_Bojkova_Caco-2_10h_Down 13 Proteome Caco-2 SARS-CoV-2 Control 10h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 6 (46%) 9 (69%)
COVID219 Proteome_Bojkova_Caco-2_10h_Up 3 Proteome Caco-2 SARS-CoV-2 Control 10h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 2 (67%) 2 (67%)
COVID220 Proteome_Bojkova_Caco-2_24h_Down 72 Proteome Caco-2 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 24 (33%) 67 (93%)
COVID221 Proteome_Bojkova_Caco-2_24h_Up 42 Proteome Caco-2 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 9 (21%) 30 (71%)
COVID222 Proteome_Bojkova_Caco-2_2h_Down 3 Proteome Caco-2 SARS-CoV-2 Control 2h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 1 (33%) 0 (0%)
COVID223 Proteome_Bojkova_Caco-2_2h_Up 2 Proteome Caco-2 SARS-CoV-2 Control 2h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 2 (100%) 1 (50%)
COVID224 Proteome_Bojkova_Caco-2_6h_Down 3 Proteome Caco-2 SARS-CoV-2 Control 6h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 1 (33%) 2 (67%)
COVID225 Proteome_Bojkova_Caco-2_6h_Up 51 Proteome Caco-2 SARS-CoV-2 Control 6h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 13 (25%) 40 (78%)
COVID226 Translatome_Bojkova_Caco-2_10h_Down 83 Translatome Caco-2 SARS-CoV-2 Control 10h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 32 (39%) 70 (84%)
COVID227 Translatome_Bojkova_Caco-2_10h_Up 1 Translatome Caco-2 SARS-CoV-2 Control 10h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 0 (0%) 1 (100%)
COVID228 Translatome_Bojkova_Caco-2_24h_Down 170 Translatome Caco-2 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 45 (26%) 151 (89%)
COVID229 Translatome_Bojkova_Caco-2_24h_Up 44 Translatome Caco-2 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 5 (11%) 39 (89%)
COVID230 Translatome_Bojkova_Caco-2_2h_Down 18 Translatome Caco-2 SARS-CoV-2 Control 2h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 12 (67%) 17 (94%)
COVID231 Translatome_Bojkova_Caco-2_2h_Up 13 Translatome Caco-2 SARS-CoV-2 Control 2h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 3 (23%) 11 (85%)
COVID232 Translatome_Bojkova_Caco-2_6h_Down 18 Translatome Caco-2 SARS-CoV-2 Control 6h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 3 (17%) 14 (78%)
COVID233 Translatome_Bojkova_Caco-2_6h_Up 3 Translatome Caco-2 SARS-CoV-2 Control 6h Significance defined by Abs(Log2FC)>0.585 and P<0.05. Features sorted by pvalue. 3 (100%) 3 (100%)

6. Sun et al. Comparative transcriptome analysis reveals the intensive early-stage responses of host cells to SARS-CoV-2 infection biorxiv pre-print
Calu-3 infection with SARS-CoV-2, SARS-CoV, and MERS-CoV.
Only SARS-CoV-2 results available in supplement
 IsOMICS RNA-Seq,  SampleType in vitro,  CellType Calu-3,  VirusStrain SARS-CoV-2, MERS CoV, SARS-CoV ,  Timepoints 7, 12, 24 h,  Perturbations ,  HasCompleteData Yes,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined1303       1108 (85%)
COVID035 RNA_Sun_Calu-3_0h_Down 171 RNA-seq Calu-3 SARS-CoV-2 uninfected 0h 9 (5%) 93 (54%)
COVID036 RNA_Sun_Calu-3_0h_Up 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 0h 87 (29%) 271 (90%)
COVID037 RNA_Sun_Calu-3_12h_Down 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 12h 130 (43%) 275 (92%)
COVID038 RNA_Sun_Calu-3_12h_Up 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 12h 199 (66%) 268 (89%)
COVID039 RNA_Sun_Calu-3_24h_Down 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 24h 131 (44%) 273 (91%)
COVID040 RNA_Sun_Calu-3_24h_Up 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 24h 192 (64%) 275 (92%)
COVID041 RNA_Sun_Calu-3_7h_Down 11 RNA-seq Calu-3 SARS-CoV-2 uninfected 7h 1 (9%) 9 (82%)
COVID042 RNA_Sun_Calu-3_7h_Up 63 RNA-seq Calu-3 SARS-CoV-2 uninfected 7h 57 (90%) 61 (97%)

7. Wilk et al. A single-cell atlas of the peripheral immune response to severe COVID-19 medRxiv pre-print

 IsOMICS ,  SampleType patient samples,  CellType ,  VirusStrain ,  Timepoints n/a,  Perturbations ,  HasCompleteData Yes,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined1043       883 (85%)
COVID244 RNA_Wilk_CD14+Monocytes_patient-C1A-mild_Up 80 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 80 (100%) 80 (100%)
COVID245 RNA_Wilk_CD14+Monocytes_patient-C1A-mild_Down 55 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 53 (96%) 52 (95%)
COVID246 RNA_Wilk_CD14+Monocytes_patient-C1B-severe_Up 77 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 75 (97%) 75 (97%)
COVID247 RNA_Wilk_CD14+Monocytes_patient-C1B-severe_Down 58 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 58 (100%) 57 (98%)
COVID248 RNA_Wilk_CD14+Monocytes_patient-C2_Up 63 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 58 (92%) 61 (97%)
COVID249 RNA_Wilk_CD14+Monocytes_patient-C2_Down 62 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 59 (95%) 55 (89%)
COVID250 RNA_Wilk_CD14+Monocytes_patient-C3_Up 51 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 49 (96%) 49 (96%)
COVID251 RNA_Wilk_CD14+Monocytes_patient-C3_Down 58 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 58 (100%) 55 (95%)
COVID252 RNA_Wilk_CD14+Monocytes_patient-C4_Up 78 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 78 (100%) 76 (97%)
COVID253 RNA_Wilk_CD14+Monocytes_patient-C4_Down 97 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 92 (95%) 89 (92%)
COVID254 RNA_Wilk_CD14+Monocytes_patient-C5_Up 104 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 101 (97%) 99 (95%)
COVID255 RNA_Wilk_CD14+Monocytes_patient-C5_Down 142 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 113 (80%) 131 (92%)
COVID256 RNA_Wilk_CD14+Monocytes_patient-C6_Up 154 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 137 (89%) 143 (93%)
COVID257 RNA_Wilk_CD14+Monocytes_patient-C6_Down 86 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 80 (93%) 81 (94%)
COVID258 RNA_Wilk_CD14+Monocytes_patient-C7_Up 32 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 29 (91%) 29 (91%)
COVID259 RNA_Wilk_CD14+Monocytes_patient-C7_Down 33 scRNA-seq CD14+ Monocytes SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 33 (100%) 30 (91%)
COVID260 RNA_Wilk_CD16+Monocytes_patient-C1A-mild_Up 74 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 66 (89%) 70 (95%)
COVID261 RNA_Wilk_CD16+Monocytes_patient-C1A-mild_Down 17 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 17 (100%) 16 (94%)
COVID262 RNA_Wilk_CD16+Monocytes_patient-C1B-severe_Up 49 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 43 (88%) 48 (98%)
COVID263 RNA_Wilk_CD16+Monocytes_patient-C1B-severe_Down 12 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 12 (100%) 12 (100%)
COVID264 RNA_Wilk_CD16+Monocytes_patient-C3_Up 39 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 35 (90%) 36 (92%)
COVID265 RNA_Wilk_CD16+Monocytes_patient-C3_Down 1 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 1 (100%) 1 (100%)
COVID266 RNA_Wilk_CD16+Monocytes_patient-C4_Up 77 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 71 (92%) 77 (100%)
COVID267 RNA_Wilk_CD16+Monocytes_patient-C4_Down 16 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 16 (100%) 15 (94%)
COVID268 RNA_Wilk_CD16+Monocytes_patient-C5_Up 100 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 72 (72%) 91 (91%)
COVID269 RNA_Wilk_CD16+Monocytes_patient-C5_Down 6 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 6 (100%) 6 (100%)
COVID270 RNA_Wilk_CD16+Monocytes_patient-C6_Up 29 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 25 (86%) 26 (90%)
COVID271 RNA_Wilk_CD16+Monocytes_patient-C7_Up 26 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 26 (100%) 26 (100%)
COVID272 RNA_Wilk_CD16+Monocytes_patient-C7_Down 27 scRNA-seq CD16+ Monocytes SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 20 (74%) 24 (89%)
COVID273 RNA_Wilk_Dendritic-cells_patient-C1A-mild_Up 40 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 40 (100%) 40 (100%)
COVID274 RNA_Wilk_Dendritic-cells_patient-C1A-mild_Down 1 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 1 (100%) 1 (100%)
COVID275 RNA_Wilk_Dendritic-cells_patient-C1B-severe_Up 15 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 14 (93%) 15 (100%)
COVID276 RNA_Wilk_Dendritic-cells_patient-C1B-severe_Down 1 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 1 (100%) 1 (100%)
COVID277 RNA_Wilk_Dendritic-cells_patient-C2_Up 72 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 3 (4%) 33 (46%)
COVID278 RNA_Wilk_Dendritic-cells_patient-C3_Up 11 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 11 (100%) 9 (82%)
COVID279 RNA_Wilk_Dendritic-cells_patient-C3_Down 1 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 1 (100%) 1 (100%)
COVID280 RNA_Wilk_Dendritic-cells_patient-C4_Up 25 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 25 (100%) 25 (100%)
COVID281 RNA_Wilk_Dendritic-cells_patient-C4_Down 18 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 18 (100%) 16 (89%)
COVID282 RNA_Wilk_Dendritic-cells_patient-C5_Up 73 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 67 (92%) 72 (99%)
COVID283 RNA_Wilk_Dendritic-cells_patient-C5_Down 22 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 21 (95%) 20 (91%)
COVID284 RNA_Wilk_Dendritic-cells_patient-C6_Up 16 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 12 (75%) 12 (75%)
COVID285 RNA_Wilk_Dendritic-cells_patient-C7_Up 29 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 27 (93%) 27 (93%)
COVID286 RNA_Wilk_Dendritic-cells_patient-C7_Down 26 scRNA-seq Dendritic cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 21 (81%) 24 (92%)
COVID287 RNA_Wilk_NK-cells_patient-C1A-mild_Up 34 scRNA-seq NK cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 34 (100%) 32 (94%)
COVID288 RNA_Wilk_NK-cells_patient-C1A-mild_Down 16 scRNA-seq NK cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 16 (100%) 15 (94%)
COVID289 RNA_Wilk_NK-cells_patient-C1B-severe_Up 12 scRNA-seq NK cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 8 (67%) 8 (67%)
COVID290 RNA_Wilk_NK-cells_patient-C1B-severe_Down 14 scRNA-seq NK cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 14 (100%) 12 (86%)
COVID291 RNA_Wilk_NK-cells_patient-C2_Up 5 scRNA-seq NK cells SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 4 (80%) 4 (80%)
COVID292 RNA_Wilk_NK-cells_patient-C2_Down 7 scRNA-seq NK cells SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 5 (71%) 7 (100%)
COVID293 RNA_Wilk_NK-cells_patient-C3_Up 25 scRNA-seq NK cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 23 (92%) 24 (96%)
COVID294 RNA_Wilk_NK-cells_patient-C3_Down 8 scRNA-seq NK cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 8 (100%) 7 (88%)
COVID295 RNA_Wilk_NK-cells_patient-C4_Up 24 scRNA-seq NK cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 23 (96%) 23 (96%)
COVID296 RNA_Wilk_NK-cells_patient-C4_Down 22 scRNA-seq NK cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 22 (100%) 21 (95%)
COVID297 RNA_Wilk_NK-cells_patient-C5_Up 52 scRNA-seq NK cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 43 (83%) 48 (92%)
COVID298 RNA_Wilk_NK-cells_patient-C5_Down 29 scRNA-seq NK cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 26 (90%) 27 (93%)
COVID299 RNA_Wilk_NK-cells_patient-C6_Up 30 scRNA-seq NK cells SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 28 (93%) 30 (100%)
COVID300 RNA_Wilk_NK-cells_patient-C6_Down 4 scRNA-seq NK cells SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 4 (100%) 4 (100%)
COVID301 RNA_Wilk_NK-cells_patient-C7_Up 5 scRNA-seq NK cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 5 (100%) 5 (100%)
COVID302 RNA_Wilk_NK-cells_patient-C7_Down 30 scRNA-seq NK cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 20 (67%) 27 (90%)
COVID303 RNA_Wilk_CD8+T-cells_patient-C1A-mild_Up 19 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 19 (100%) 19 (100%)
COVID304 RNA_Wilk_CD8+T-cells_patient-C1A-mild_Down 22 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 20 (91%) 18 (82%)
COVID305 RNA_Wilk_CD8+T-cells_patient-C1B-severe_Up 10 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 10 (100%) 9 (90%)
COVID306 RNA_Wilk_CD8+T-cells_patient-C1B-severe_Down 9 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 9 (100%) 8 (89%)
COVID307 RNA_Wilk_CD8+T-cells_patient-C2_Up 10 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 10 (100%) 9 (90%)
COVID308 RNA_Wilk_CD8+T-cells_patient-C2_Down 10 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 9 (90%) 9 (90%)
COVID309 RNA_Wilk_CD8+T-cells_patient-C3_Up 33 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 31 (94%) 31 (94%)
COVID310 RNA_Wilk_CD8+T-cells_patient-C3_Down 5 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 5 (100%) 5 (100%)
COVID311 RNA_Wilk_CD8+T-cells_patient-C4_Up 22 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 22 (100%) 22 (100%)
COVID312 RNA_Wilk_CD8+T-cells_patient-C4_Down 31 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 31 (100%) 31 (100%)
COVID313 RNA_Wilk_CD8+T-cells_patient-C5_Up 43 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 41 (95%) 42 (98%)
COVID314 RNA_Wilk_CD8+T-cells_patient-C5_Down 45 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 39 (87%) 41 (91%)
COVID315 RNA_Wilk_CD8+T-cells_patient-C6_Up 41 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 37 (90%) 40 (98%)
COVID316 RNA_Wilk_CD8+T-cells_patient-C6_Down 11 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 11 (100%) 11 (100%)
COVID317 RNA_Wilk_CD8+T-cells_patient-C7_Up 3 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 3 (100%) 2 (67%)
COVID318 RNA_Wilk_CD8+T-cells_patient-C7_Down 12 scRNA-seq CD8+ T cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 10 (83%) 10 (83%)
COVID319 RNA_Wilk_CD4+T-cells_patient-C1A-mild_Up 40 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 40 (100%) 40 (100%)
COVID320 RNA_Wilk_CD4+T-cells_patient-C1A-mild_Down 34 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 33 (97%) 31 (91%)
COVID321 RNA_Wilk_CD4+T-cells_patient-C1B-severe_Up 13 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 13 (100%) 13 (100%)
COVID322 RNA_Wilk_CD4+T-cells_patient-C1B-severe_Down 7 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 7 (100%) 7 (100%)
COVID323 RNA_Wilk_CD4+T-cells_patient-C2_Up 21 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 18 (86%) 20 (95%)
COVID324 RNA_Wilk_CD4+T-cells_patient-C2_Down 10 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 10 (100%) 9 (90%)
COVID325 RNA_Wilk_CD4+T-cells_patient-C3_Up 15 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 14 (93%) 15 (100%)
COVID326 RNA_Wilk_CD4+T-cells_patient-C3_Down 6 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 6 (100%) 6 (100%)
COVID327 RNA_Wilk_CD4+T-cells_patient-C4_Up 24 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 24 (100%) 24 (100%)
COVID328 RNA_Wilk_CD4+T-cells_patient-C4_Down 31 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 30 (97%) 29 (94%)
COVID329 RNA_Wilk_CD4+T-cells_patient-C5_Up 38 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 38 (100%) 38 (100%)
COVID330 RNA_Wilk_CD4+T-cells_patient-C5_Down 32 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 31 (97%) 29 (91%)
COVID331 RNA_Wilk_CD4+T-cells_patient-C6_Up 38 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 32 (84%) 35 (92%)
COVID332 RNA_Wilk_CD4+T-cells_patient-C6_Down 12 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 11 (92%) 11 (92%)
COVID333 RNA_Wilk_CD4+T-cells_patient-C7_Up 8 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 7 (88%) 7 (88%)
COVID334 RNA_Wilk_CD4+T-cells_patient-C7_Down 11 scRNA-seq CD4+ T cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 10 (91%) 10 (91%)
COVID335 RNA_Wilk_B-cells_patient-C1A-mild_Up 63 scRNA-seq B cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 63 (100%) 62 (98%)
COVID336 RNA_Wilk_B-cells_patient-C1A-mild_Down 60 scRNA-seq B cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 60 (100%) 52 (87%)
COVID337 RNA_Wilk_B-cells_patient-C1B-severe_Up 104 scRNA-seq B cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 97 (93%) 95 (91%)
COVID338 RNA_Wilk_B-cells_patient-C1B-severe_Down 76 scRNA-seq B cells SARS-CoV-2 Healthy 11d post onset SARS-CoV-2 patient C1, male, 60-69 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 17. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 76 (100%) 70 (92%)
COVID339 RNA_Wilk_B-cells_patient-C2_Up 34 scRNA-seq B cells SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 33 (97%) 34 (100%)
COVID340 RNA_Wilk_B-cells_patient-C2_Down 19 scRNA-seq B cells SARS-CoV-2 Healthy 16d post onset SARS-CoV-2 patient C2, male, 40-49 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 19 (100%) 17 (89%)
COVID341 RNA_Wilk_B-cells_patient-C3_Up 82 scRNA-seq B cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 80 (98%) 78 (95%)
COVID342 RNA_Wilk_B-cells_patient-C3_Down 28 scRNA-seq B cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C3, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 25. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 28 (100%) 26 (93%)
COVID343 RNA_Wilk_B-cells_patient-C4_Up 121 scRNA-seq B cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 104 (86%) 114 (94%)
COVID344 RNA_Wilk_B-cells_patient-C4_Down 169 scRNA-seq B cells SARS-CoV-2 Healthy 9d post onset SARS-CoV-2 patient C4, male, 30-39 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 16. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 166 (98%) 147 (87%)
COVID345 RNA_Wilk_B-cells_patient-C5_Up 116 scRNA-seq B cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 107 (92%) 110 (95%)
COVID346 RNA_Wilk_B-cells_patient-C5_Down 181 scRNA-seq B cells SARS-CoV-2 Healthy 15d post onset SARS-CoV-2 patient C5, male, 50-59 yr, ventilated/ARDS: no, admission level: ICU, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 164 (91%) 157 (87%)
COVID347 RNA_Wilk_B-cells_patient-C6_Up 110 scRNA-seq B cells SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 51 (46%) 100 (91%)
COVID348 RNA_Wilk_B-cells_patient-C6_Down 33 scRNA-seq B cells SARS-CoV-2 Healthy 2d post onset SARS-CoV-2 patient C6, male, >80 yr, ventilated/ARDS: yes, admission level: ICU, days intubated: 11. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 33 (100%) 32 (97%)
COVID349 RNA_Wilk_B-cells_patient-C7_Up 5 scRNA-seq B cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 5 (100%) 5 (100%)
COVID350 RNA_Wilk_B-cells_patient-C7_Down 39 scRNA-seq B cells SARS-CoV-2 Healthy 12d post onset SARS-CoV-2 patient C7, male, 20-29 yr, ventilated/ARDS: no, admission level: floor, days intubated: 0. Singificance defined by p-value < 0.05 and abs(log2FC) >= 0.25. Features sorted by log2FC. 37 (95%) 36 (92%)

8. Lieberman et al. In vivo antiviral host response to SARS-CoV-2 by viral load, sex, and age bioRxiv pre-print
Nasopharyngeal swabs from 430 SARS-CoV-2 patients and 54 controls.

 IsOMICS RNA-seq,  SampleType patient samples,  CellType SARS CoV2 patients,  VirusStrain SARS-CoV2,  Timepoints n/a,  Perturbations ,  HasCompleteData ,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined414       350 (85%)
COVID238 RNA_Lieberman_Nasopharynx_Infected_vs_Neg_Down 42 RNA-seq Nasopharynx SARS-CoV-2 Negative Significance defined by Abs(Log2FC)>1 and Adj P<0.1. Features sorted by pvalue. 8 (19%) 41 (98%)
COVID239 RNA_Lieberman_Nasopharynx_Infected_vs_Neg_Up 41 RNA-seq Nasopharynx SARS-CoV-2 Negative Significance defined by Abs(Log2FC)>1 and Adj P<0.1. Features sorted by pvalue. 22 (54%) 39 (95%)
COVID240 RNA_Lieberman_Nasopharynx_High_vs_Low_Down 188 RNA-seq Nasopharynx SARS-CoV-2 High Viral Load SARS-CoV-2 Low Viral Load Significance defined by Adj P<0.1. Features sorted by pvalue. 9 (5%) 153 (81%)
COVID241 RNA_Lieberman_Nasopharynx_High_vs_Low_Up 173 RNA-seq Nasopharynx SARS-CoV-2 High Viral Load SARS-CoV-2 Low Viral Load Significance defined by Adj P<0.1. Features sorted by pvalue. 21 (12%) 146 (84%)

9. Bouhaddou et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection Cell peer reviewed
Phosphoproteomics study of CoV-2 infected Vero-E6 cells.

 IsOMICS Phosphoproteomics,  SampleType in vitro,  CellType Vero-E6 cells,  VirusStrain SARS-CoV2,  Timepoints 0 to 24h,  Perturbations ,  HasCompleteData ,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined1264       1054 (83%)
COVID055 Phosphoproteome_Bouhaddou_Vero_E6_0h_Down 277 Phosphoproteome Vero_E6 SARS-CoV-2 Control 0h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 217 (78%) 238 (86%)
COVID056 Phosphoproteome_Bouhaddou_Vero_E6_0h_Up 184 Phosphoproteome Vero_E6 SARS-CoV-2 Control 0h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 145 (79%) 160 (87%)
COVID057 Phosphoproteome_Bouhaddou_Vero_E6_12h_Down 300 Phosphoproteome Vero_E6 SARS-CoV-2 Control 12h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 290 (97%) 260 (87%)
COVID058 Phosphoproteome_Bouhaddou_Vero_E6_12h_Up 300 Phosphoproteome Vero_E6 SARS-CoV-2 Control 12h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 277 (92%) 254 (85%)
COVID059 Phosphoproteome_Bouhaddou_Vero_E6_24h_Down 300 Phosphoproteome Vero_E6 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 254 (85%) 254 (85%)
COVID060 Phosphoproteome_Bouhaddou_Vero_E6_24h_Up 300 Phosphoproteome Vero_E6 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 230 (77%) 256 (85%)
COVID061 Phosphoproteome_Bouhaddou_Vero_E6_2h_Down 300 Phosphoproteome Vero_E6 SARS-CoV-2 Control 2h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 249 (83%) 255 (85%)
COVID062 Phosphoproteome_Bouhaddou_Vero_E6_2h_Up 300 Phosphoproteome Vero_E6 SARS-CoV-2 Control 2h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 272 (91%) 252 (84%)
COVID063 Phosphoproteome_Bouhaddou_Vero_E6_4h_Down 197 Phosphoproteome Vero_E6 SARS-CoV-2 Control 4h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 187 (95%) 171 (87%)
COVID064 Phosphoproteome_Bouhaddou_Vero_E6_4h_Up 262 Phosphoproteome Vero_E6 SARS-CoV-2 Control 4h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 245 (94%) 217 (83%)
COVID065 Phosphoproteome_Bouhaddou_Vero_E6_8h_Down 300 Phosphoproteome Vero_E6 SARS-CoV-2 Control 8h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 276 (92%) 263 (88%)
COVID066 Phosphoproteome_Bouhaddou_Vero_E6_8h_Up 300 Phosphoproteome Vero_E6 SARS-CoV-2 Control 8h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 280 (93%) 252 (84%)
COVID067 Proteome_Bouhaddou_Vero_E6_0h_Down 10 Proteome Vero_E6 SARS-CoV-2 Control 0h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 4 (40%) 9 (90%)
COVID068 Proteome_Bouhaddou_Vero_E6_0h_Up 1 Proteome Vero_E6 SARS-CoV-2 Control 0h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 0 (0%) 1 (100%)
COVID069 Proteome_Bouhaddou_Vero_E6_12h_Down 52 Proteome Vero_E6 SARS-CoV-2 Control 12h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 49 (94%) 49 (94%)
COVID070 Proteome_Bouhaddou_Vero_E6_12h_Up 6 Proteome Vero_E6 SARS-CoV-2 Control 12h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 6 (100%) 3 (50%)
COVID071 Proteome_Bouhaddou_Vero_E6_24h_Down 95 Proteome Vero_E6 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 60 (63%) 86 (91%)
COVID072 Proteome_Bouhaddou_Vero_E6_24h_Up 15 Proteome Vero_E6 SARS-CoV-2 Control 24h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 7 (47%) 9 (60%)
COVID073 Proteome_Bouhaddou_Vero_E6_2h_Down 42 Proteome Vero_E6 SARS-CoV-2 Control 2h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 39 (93%) 39 (93%)
COVID074 Proteome_Bouhaddou_Vero_E6_2h_Up 6 Proteome Vero_E6 SARS-CoV-2 Control 2h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 4 (67%) 3 (50%)
COVID075 Proteome_Bouhaddou_Vero_E6_4h_Down 32 Proteome Vero_E6 SARS-CoV-2 Control 4h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 32 (100%) 29 (91%)
COVID076 Proteome_Bouhaddou_Vero_E6_4h_Up 3 Proteome Vero_E6 SARS-CoV-2 Control 4h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 3 (100%) 0 (0%)
COVID077 Proteome_Bouhaddou_Vero_E6_8h_Down 44 Proteome Vero_E6 SARS-CoV-2 Control 8h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 41 (93%) 41 (93%)
COVID078 Proteome_Bouhaddou_Vero_E6_8h_Up 6 Proteome Vero_E6 SARS-CoV-2 Control 8h Significance defined by Abs(Log2FC)>1 and Adj P<0.05 as in the publication. Features sorted by pvalue. 5 (83%) 3 (50%)

10. Gordon et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing Nature peer reviewed
SARS-CoV-2-Human Protein-Protein Interaction Map.

 IsOMICS Proteomics (APMS),  SampleType in vitro,  CellType HEK293T,  VirusStrain SARS-CoV-2 (USA-WA1/2020),  Timepoints n/a,  Perturbations ,  HasCompleteData yes,  GeneListSource .

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined332       270 (81%)
COVID081 Interactome_Gordon_HEK-293T_38h_E 6 Interactome HEK-293T E 38h 0 (0%) 5 (83%)
COVID082 Interactome_Gordon_HEK-293T_38h_M 30 Interactome HEK-293T M 38h 0 (0%) 24 (80%)
COVID083 Interactome_Gordon_HEK-293T_38h_N 15 Interactome HEK-293T N 38h 0 (0%) 14 (93%)
COVID084 Interactome_Gordon_HEK-293T_38h_NSP1 6 Interactome HEK-293T NSP1 38h 0 (0%) 6 (100%)
COVID085 Interactome_Gordon_HEK-293T_38h_NSP10 5 Interactome HEK-293T NSP10 38h 0 (0%) 4 (80%)
COVID086 Interactome_Gordon_HEK-293T_38h_NSP11 1 Interactome HEK-293T NSP11 38h 0 (0%) 0 (0%)
COVID087 Interactome_Gordon_HEK-293T_38h_NSP12 20 Interactome HEK-293T NSP12 38h 0 (0%) 17 (85%)
COVID088 Interactome_Gordon_HEK-293T_38h_NSP13 40 Interactome HEK-293T NSP13 38h 0 (0%) 26 (65%)
COVID089 Interactome_Gordon_HEK-293T_38h_NSP14 3 Interactome HEK-293T NSP14 38h 0 (0%) 3 (100%)
COVID090 Interactome_Gordon_HEK-293T_38h_NSP15 3 Interactome HEK-293T NSP15 38h 0 (0%) 2 (67%)
COVID091 Interactome_Gordon_HEK-293T_38h_NSP2 7 Interactome HEK-293T NSP2 38h 0 (0%) 7 (100%)
COVID092 Interactome_Gordon_HEK-293T_38h_NSP4 8 Interactome HEK-293T NSP4 38h 0 (0%) 7 (88%)
COVID093 Interactome_Gordon_HEK-293T_38h_NSP5 1 Interactome HEK-293T NSP5 38h 0 (0%) 1 (100%)
COVID094 Interactome_Gordon_HEK-293T_38h_NSP5_C145A 2 Interactome HEK-293T NSP5_C145A 38h 0 (0%) 1 (50%)
COVID095 Interactome_Gordon_HEK-293T_38h_NSP6 4 Interactome HEK-293T NSP6 38h 0 (0%) 3 (75%)
COVID096 Interactome_Gordon_HEK-293T_38h_NSP7 32 Interactome HEK-293T NSP7 38h 0 (0%) 27 (84%)
COVID097 Interactome_Gordon_HEK-293T_38h_NSP8 24 Interactome HEK-293T NSP8 38h 0 (0%) 19 (79%)
COVID098 Interactome_Gordon_HEK-293T_38h_NSP9 16 Interactome HEK-293T NSP9 38h 0 (0%) 15 (94%)
COVID099 Interactome_Gordon_HEK-293T_38h_ORF10 9 Interactome HEK-293T ORF10 38h 0 (0%) 9 (100%)
COVID100 Interactome_Gordon_HEK-293T_38h_ORF3A 8 Interactome HEK-293T ORF3A 38h 0 (0%) 8 (100%)
COVID101 Interactome_Gordon_HEK-293T_38h_ORF3B 1 Interactome HEK-293T ORF3B 38h 0 (0%) 1 (100%)
COVID102 Interactome_Gordon_HEK-293T_38h_ORF6 3 Interactome HEK-293T ORF6 38h 0 (0%) 3 (100%)
COVID103 Interactome_Gordon_HEK-293T_38h_ORF7A 2 Interactome HEK-293T ORF7A 38h 0 (0%) 2 (100%)
COVID104 Interactome_Gordon_HEK-293T_38h_ORF8 47 Interactome HEK-293T ORF8 38h 0 (0%) 33 (70%)
COVID105 Interactome_Gordon_HEK-293T_38h_ORF9B 11 Interactome HEK-293T ORF9B 38h 0 (0%) 11 (100%)
COVID106 Interactome_Gordon_HEK-293T_38h_ORF9C 26 Interactome HEK-293T ORF9C 38h 0 (0%) 20 (77%)
COVID107 Interactome_Gordon_HEK-293T_38h_S 2 Interactome HEK-293T S 38h 0 (0%) 2 (100%)

11. Lamers et al. SARS-CoV-2 productively infects human gut enterocytes Science peer reviewed
Bulk RNA sequencing of SARS-CoV and SARS-CoV-2 infected human intestinal organoids.

 IsOMICS RNA-Seq,  SampleType in vitro,  CellType human intestinal organoids,  VirusStrain SARS-CoV-2,  Timepoints 24, 60 h,  Perturbations ,  HasCompleteData Yes,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined477       379 (79%)
COVID025 RNA_Lamers_intestinal-organoid_differentiated_Down 46 RNA-seq intestinal organoid (differentiation medium) SARS-CoV-2 uninfected 60h 22 (48%) 36 (78%)
COVID026 RNA_Lamers_intestinal-organoid_differentiated_Up 36 RNA-seq intestinal organoid (differentiation medium) SARS-CoV-2 uninfected 60h 14 (39%) 28 (78%)
COVID027 RNA_Lamers_intestinal-organoid_expansion_Down 264 RNA-seq intestinal-organoid (expansion medium) SARS-CoV-2 uninfected 60h 20 (8%) 208 (79%)
COVID028 RNA_Lamers_intestinal-organoid_expansion_Up 167 RNA-seq intestinal-organoid (expansion medium) SARS-CoV-2 uninfected 60h 16 (10%) 139 (83%)

12. Blanco-Melo et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19 Cell peer reviewed (pre-proof)

 IsOMICS RNA-Seq,  SampleType in vitro, in vivo model, patient samples,  CellType primary human lung epithelium (NHBE), A549, Calu-3, ferrets, patient samples,  VirusStrain SARS-CoV-2 (USA-WA1/2020),  Timepoints multiple, depending on model system,  Perturbations ,  HasCompleteData yes,  GeneListSource GEO read counts.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined1793       1424 (79%)
COVID007 RNA_Blanco-Melo_A549_Down 300 RNA-seq A549 SARS-CoV-2 uninfected 9h 139 (46%) 240 (80%)
COVID008 RNA_Blanco-Melo_A549_Up 300 RNA-seq A549 SARS-CoV-2 uninfected 9h 108 (36%) 249 (83%)
COVID009 RNA_Blanco-Melo_A549-ACE2_Down 207 RNA-seq A549 w/ exogenous ACE2 SARS-CoV-2 uninfected 9h 54 (26%) 165 (80%)
COVID010 RNA_Blanco-Melo_A549-ACE2_Up 300 RNA-seq A549 w/ exogenous ACE2 SARS-CoV-2 uninfected 9h 90 (30%) 237 (79%)
COVID011 RNA_Blanco-Melo_A549-ACE2-ruxolitinib_Down 233 RNA-seq A549 w/ exogenous ACE2 SARS-CoV-2 and ruxolitinib SARS-CoV-2 9h 142 (61%) 210 (90%)
COVID012 RNA_Blanco-Melo_A549-ACE2-ruxolitinib_Up 8 RNA-seq A549 w/ exogenous ACE2 SARS-CoV-2 and ruxolitinib SARS-CoV-2 9h 5 (62%) 6 (75%)
COVID013 RNA_Blanco-Melo_A549-low-MOI_Down 1 RNA-seq A549 SARS-CoV-2 (low MOI) uninfected 9h 1 (100%) 1 (100%)
COVID014 RNA_Blanco-Melo_A549-low-MOI_Up 35 RNA-seq A549 SARS-CoV-2 (low MOI) uninfected 9h 35 (100%) 35 (100%)
COVID015 RNA_Blanco-Melo_Calu-3_Down 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 9h 131 (44%) 247 (82%)
COVID016 RNA_Blanco-Melo_Calu-3_Up 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 9h 219 (73%) 288 (96%)
COVID017 RNA_Blanco-Melo_Lung_Down 259 RNA-seq Lung SARS-CoV-2 uninfected post-mortem 73 (28%) 185 (71%)
COVID018 RNA_Blanco-Melo_Lung_Up 83 RNA-seq Lung SARS-CoV-2 uninfected post-mortem 23 (28%) 64 (77%)
COVID019 RNA_Blanco-Melo_NHBE_Down 11 RNA-seq NHBE SARS-CoV-2 uninfected 24h 1 (9%) 8 (73%)
COVID020 RNA_Blanco-Melo_NHBE_Up 85 RNA-seq NHBE SARS-CoV-2 uninfected 24h 62 (73%) 78 (92%)

13. Wyler et al. Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention GEO pre-print
Gene expression profiling of SARS-CoV-1/2 infected human cell lines at bulk and single-cell level.
Includes small RNA-seq in addition to polyA/total RNA. H1299 cell line ignored since few genes change overall.
 IsOMICS RNA-Seq, scRNA-seq,  SampleType in vitro,  CellType Calu-3, Caco-2, H1299,  VirusStrain SARS-CoV-2,  Timepoints 4, 8, 12, 24, 36 h,  Perturbations ,  HasCompleteData Yes,  GeneListSource GEO read counts.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined1033       820 (79%)
COVID043 RNA_Wyler_Caco-2_12h_Down 123 RNA-seq Caco-2 SARS-CoV-2 uninfected 12h 37 (30%) 83 (67%)
COVID044 RNA_Wyler_Caco-2_12h_Up 28 RNA-seq Caco-2 SARS-CoV-2 uninfected 12h 17 (61%) 22 (79%)
COVID045 RNA_Wyler_Caco-2_24h_Down 32 RNA-seq Caco-2 SARS-CoV-2 uninfected 24h 20 (62%) 24 (75%)
COVID046 RNA_Wyler_Caco-2_24h_Up 95 RNA-seq Caco-2 SARS-CoV-2 uninfected 24h 39 (41%) 78 (82%)
COVID047 RNA_Wyler_Calu-3_12h_Down 188 RNA-seq Calu-3 SARS-CoV-2 uninfected 12h 42 (22%) 120 (64%)
COVID048 RNA_Wyler_Calu-3_12h_Up 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 12h 215 (72%) 290 (97%)
COVID049 RNA_Wyler_Calu-3_24h_Down 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 24h 50 (17%) 225 (75%)
COVID050 RNA_Wyler_Calu-3_24h_Up 300 RNA-seq Calu-3 SARS-CoV-2 uninfected 24h 219 (73%) 287 (96%)

14. Shen et al. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera Cell peer reviewed
Proteomics comparison of sera samples from healthy, severe and non-severe COVID-19 patients, and non-COVID-19 patients.

 IsOMICS Proteomics and metabolomics,  SampleType patient and healthy samples,  CellType Healthy, non-COVID-19, and SARS CoV2 patient sera,  VirusStrain ,  Timepoints N/A,  Perturbations ,  HasCompleteData Yes,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined134       106 (79%)
COVID210 Proteome_Shen_Serum-severe-vs-nonsevere_Up 25 Proteome Serum SARS-CoV-2 (severe) SARS-CoV-2 (mild) Significance defined by Supp Table. Features sorted by pvalue. 25 (100%) 20 (80%)
COVID211 Proteome_Shen_Serum-severe-vs-nonsevere_Down 16 Proteome Serum SARS-CoV-2 (severe) SARS-CoV-2 (mild) Significance defined by Supp Table. Features sorted by pvalue. 15 (94%) 13 (81%)
COVID212 Proteome_Shen_Serum-severe-vs-healthy_Up 62 Proteome Serum SARS-CoV-2 (severe) Healthy Significance defined by Supp Table. Features sorted by pvalue. 34 (55%) 53 (85%)
COVID213 Proteome_Shen_Serum-severe-vs-healthy_Down 58 Proteome Serum SARS-CoV-2 (severe) Healthy Significance defined by Supp Table. Features sorted by pvalue. 37 (64%) 41 (71%)
COVID214 Proteome_Shen_Serum-nonCovid-vs-healthy_Up 15 Proteome Serum Non-SARS-CoV-2 patient Healthy Significance defined by Supp Table. Features sorted by pvalue. 11 (73%) 14 (93%)
COVID215 Proteome_Shen_Serum-nonCovid-vs-healthy_Down 13 Proteome Serum Non-SARS-CoV-2 patient Healthy Significance defined by Supp Table. Features sorted by pvalue. 13 (100%) 9 (69%)
COVID216 Proteome_Shen_Serum-nonsevere-vs-healthy_Up 20 Proteome Serum SARS-CoV-2 (mild) Healthy Significance defined by Supp Table. Features sorted by pvalue. 15 (75%) 16 (80%)
COVID217 Proteome_Shen_Serum-nonsevere-vs-healthy_Down 23 Proteome Serum SARS-CoV-2 (mild) Healthy Significance defined by Supp Table. Features sorted by pvalue. 20 (87%) 18 (78%)

15. Li et al. Urine Proteome of COVID-19 Patients medRxiv pre-print
Proteomics analysis of urine samples from healthy, mild, and severe COVID-19 patients.

 IsOMICS Proteomics,  SampleType patient and healthy samples,  CellType Healthy and SARS CoV2 patient urine,  VirusStrain ,  Timepoints N/A,  Perturbations ,  HasCompleteData Yes,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined491       386 (79%)
COVID204 Proteome_Li_Urine-severe-vs-healthy_Up 83 Proteome Urine SARS-CoV-2 (severe) Healthy Significance defined by Supp Table. Features sorted by pvalue. 53 (64%) 69 (83%)
COVID205 Proteome_Li_Urine-severe-vs-healthy_Down 170 Proteome Urine SARS-CoV-2 (severe) Healthy Significance defined by Supp Table. Features sorted by pvalue. 106 (62%) 126 (74%)
COVID206 Proteome_Li_Urine-mild-vs-healthy_Up 86 Proteome Urine SARS-CoV-2 (mild) Healthy Significance defined by Supp Table. Features sorted by pvalue. 54 (63%) 71 (83%)
COVID207 Proteome_Li_Urine-mild-vs-healthy_Down 99 Proteome Urine SARS-CoV-2 (mild) Healthy Significance defined by Supp Table. Features sorted by pvalue. 86 (87%) 71 (72%)
COVID208 Proteome_Li_Urine-recovery-vs-healthy_Up 152 Proteome Urine SARS-CoV-2 (in recovery) Healthy Significance defined by Supp Table. Features sorted by pvalue. 45 (30%) 125 (82%)
COVID209 Proteome_Li_Urine-recovery-vs-healthy_Down 126 Proteome Urine SARS-CoV-2 (in recovery) Healthy Significance defined by Supp Table. Features sorted by pvalue. 62 (49%) 95 (75%)

16. Laurent et al. Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms BioRxiv pre-print
BioID interactome data in HEK293.

 IsOMICS Interactome by BioID,  SampleType in vitro,  CellType HEK293,  VirusStrain SARS-CoV-2 strain HKU-SZ-005b,  Timepoints 24h,  Perturbations ,  HasCompleteData Yes,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined2032       1522 (75%)
COVID363 Interactome_Laurent_HEK293_24h_E 300 Interactome HEK293 E 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 294 (98%) 235 (78%)
COVID364 Interactome_Laurent_HEK293_24h_M 300 Interactome HEK293 M 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 277 (92%) 221 (74%)
COVID365 Interactome_Laurent_HEK293_24h_N 79 Interactome HEK293 N 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 48 (61%) 54 (68%)
COVID366 Interactome_Laurent_HEK293_24h_NSP1 41 Interactome HEK293 NSP1 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 20 (49%) 35 (85%)
COVID367 Interactome_Laurent_HEK293_24h_NSP10 38 Interactome HEK293 NSP10 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 32 (84%) 26 (68%)
COVID368 Interactome_Laurent_HEK293_24h_NSP12 255 Interactome HEK293 NSP12 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 205 (80%) 173 (68%)
COVID369 Interactome_Laurent_HEK293_24h_NSP13 57 Interactome HEK293 NSP13 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 45 (79%) 49 (86%)
COVID370 Interactome_Laurent_HEK293_24h_NSP14 59 Interactome HEK293 NSP14 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 50 (85%) 45 (76%)
COVID371 Interactome_Laurent_HEK293_24h_NSP15 106 Interactome HEK293 NSP15 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 67 (63%) 79 (75%)
COVID372 Interactome_Laurent_HEK293_24h_NSP16 283 Interactome HEK293 NSP16 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 215 (76%) 207 (73%)
COVID373 Interactome_Laurent_HEK293_24h_NSP2 228 Interactome HEK293 NSP2 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 167 (73%) 162 (71%)
COVID374 Interactome_Laurent_HEK293_24h_NSP3 299 Interactome HEK293 NSP3 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 223 (75%) 228 (76%)
COVID375 Interactome_Laurent_HEK293_24h_NSP4 300 Interactome HEK293 NSP4 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 291 (97%) 216 (72%)
COVID376 Interactome_Laurent_HEK293_24h_NSP5 21 Interactome HEK293 NSP5 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 17 (81%) 15 (71%)
COVID377 Interactome_Laurent_HEK293_24h_NSP6 300 Interactome HEK293 NSP6 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 278 (93%) 237 (79%)
COVID378 Interactome_Laurent_HEK293_24h_NSP7 300 Interactome HEK293 NSP7 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 215 (72%) 201 (67%)
COVID379 Interactome_Laurent_HEK293_24h_NSP8 21 Interactome HEK293 NSP8 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 18 (86%) 19 (90%)
COVID380 Interactome_Laurent_HEK293_24h_NSP9 70 Interactome HEK293 NSP9 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 54 (77%) 59 (84%)
COVID381 Interactome_Laurent_HEK293_24h_ORF10 85 Interactome HEK293 ORF10 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 73 (86%) 73 (86%)
COVID382 Interactome_Laurent_HEK293_24h_ORF3A 300 Interactome HEK293 ORF3A 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 269 (90%) 244 (81%)
COVID383 Interactome_Laurent_HEK293_24h_ORF3B 300 Interactome HEK293 ORF3B 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 224 (75%) 235 (78%)
COVID384 Interactome_Laurent_HEK293_24h_ORF6 300 Interactome HEK293 ORF6 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 257 (86%) 231 (77%)
COVID385 Interactome_Laurent_HEK293_24h_ORF7A 300 Interactome HEK293 ORF7A 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 289 (96%) 235 (78%)
COVID386 Interactome_Laurent_HEK293_24h_ORF7B 300 Interactome HEK293 ORF7B 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 290 (97%) 227 (76%)
COVID387 Interactome_Laurent_HEK293_24h_ORF8 300 Interactome HEK293 ORF8 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 243 (81%) 240 (80%)
COVID388 Interactome_Laurent_HEK293_24h_ORF9B 111 Interactome HEK293 ORF9B 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 82 (74%) 79 (71%)
COVID389 Interactome_Laurent_HEK293_24h_ORF9C 300 Interactome HEK293 ORF9C 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 212 (71%) 237 (79%)
COVID390 Interactome_Laurent_HEK293_24h_S 300 Interactome HEK293 S 24h Performed under infection-mimicking condition for 24hrs prior proximity labeling. 285 (95%) 224 (75%)

17. Xiong et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients Emerging Microbes & Infections peer reviewed

 IsOMICS RNA-Seq,  SampleType patient samples,  CellType BALF, PBMC,  VirusStrain SARS-CoV-2,  Timepoints n/a,  Perturbations ,  HasCompleteData yes,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined1146       791 (69%)
COVID051 RNA_Xiong_BALF_Down 300 RNA-seq BALF SARS-CoV-2 uninfected 3 (1%) 253 (84%)
COVID052 RNA_Xiong_BALF_Up 300 RNA-seq BALF SARS-CoV-2 uninfected 8 (3%) 221 (74%)
COVID053 RNA_Xiong_PBMC_Down 257 RNA-seq PBMC SARS-CoV-2 uninfected 7 (3%) 116 (45%)
COVID054 RNA_Xiong_PBMC_Up 300 RNA-seq PBMC SARS-CoV-2 uninfected 4 (1%) 209 (70%)

18. Stukalov et al. Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV bioRxiv pre-print
Comprehensive SARS-CoV-2 infection profiling using proteomics and RNASeq, particularly for different SARS-CoV-2 proteins.

 IsOMICS Interactome, Proteomics, Ubiquitome, Phosphoproteome, RNA-seq,  SampleType in vitro,  CellType A549-ACE2,  VirusStrain SARS-CoV-2-MUC-IMB-1,  Timepoints 6 to 72h,  Perturbations ,  HasCompleteData ,  GeneListSource Supplemental table.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined4673       3180 (68%)
COVID108 Interactome_Stukalov_A549_72h_E 11 Interactome A549 E 72h Significance defined by Supp Table. Features sorted by pvalue. 7 (64%) 6 (55%)
COVID109 Interactome_Stukalov_A549_72h_M 138 Interactome A549 M 72h Significance defined by Supp Table. Features sorted by pvalue. 67 (49%) 87 (63%)
COVID110 Interactome_Stukalov_A549_72h_N 9 Interactome A549 N 72h Significance defined by Supp Table. Features sorted by pvalue. 6 (67%) 6 (67%)
COVID111 Interactome_Stukalov_A549_72h_NSP1 3 Interactome A549 NSP1 72h Significance defined by Supp Table. Features sorted by pvalue. 3 (100%) 2 (67%)
COVID112 Interactome_Stukalov_A549_72h_NSP12 1 Interactome A549 NSP12 72h Significance defined by Supp Table. Features sorted by pvalue. 1 (100%) 1 (100%)
COVID113 Interactome_Stukalov_A549_72h_NSP13 1 Interactome A549 NSP13 72h Significance defined by Supp Table. Features sorted by pvalue. 0 (0%) 1 (100%)
COVID114 Interactome_Stukalov_A549_72h_NSP14 2 Interactome A549 NSP14 72h Significance defined by Supp Table. Features sorted by pvalue. 0 (0%) 1 (50%)
COVID115 Interactome_Stukalov_A549_72h_NSP15 4 Interactome A549 NSP15 72h Significance defined by Supp Table. Features sorted by pvalue. 0 (0%) 3 (75%)
COVID116 Interactome_Stukalov_A549_72h_NSP16 2 Interactome A549 NSP16 72h Significance defined by Supp Table. Features sorted by pvalue. 1 (50%) 2 (100%)
COVID117 Interactome_Stukalov_A549_72h_NSP2 1 Interactome A549 NSP2 72h Significance defined by Supp Table. Features sorted by pvalue. 0 (0%) 1 (100%)
COVID118 Interactome_Stukalov_A549_72h_NSP3_MACROD 2 Interactome A549 NSP3_MACROD 72h Significance defined by Supp Table. Features sorted by pvalue. 0 (0%) 1 (50%)
COVID119 Interactome_Stukalov_A549_72h_NSP4 11 Interactome A549 NSP4 72h Significance defined by Supp Table. Features sorted by pvalue. 9 (82%) 9 (82%)
COVID120 Interactome_Stukalov_A549_72h_NSP6 82 Interactome A549 NSP6 72h Significance defined by Supp Table. Features sorted by pvalue. 44 (54%) 71 (87%)
COVID121 Interactome_Stukalov_A549_72h_NSP7 5 Interactome A549 NSP7 72h Significance defined by Supp Table. Features sorted by pvalue. 4 (80%) 4 (80%)
COVID122 Interactome_Stukalov_A549_72h_NSP8 3 Interactome A549 NSP8 72h Significance defined by Supp Table. Features sorted by pvalue. 2 (67%) 3 (100%)
COVID123 Interactome_Stukalov_A549_72h_NSP9 6 Interactome A549 NSP9 72h Significance defined by Supp Table. Features sorted by pvalue. 4 (67%) 4 (67%)
COVID124 Interactome_Stukalov_A549_72h_ORF3 300 Interactome A549 ORF3 72h Significance defined by Supp Table. Features sorted by pvalue. 197 (66%) 224 (75%)
COVID125 Interactome_Stukalov_A549_72h_ORF7A 55 Interactome A549 ORF7A 72h Significance defined by Supp Table. Features sorted by pvalue. 39 (71%) 31 (56%)
COVID126 Interactome_Stukalov_A549_72h_ORF7B 300 Interactome A549 ORF7B 72h Significance defined by Supp Table. Features sorted by pvalue. 203 (68%) 211 (70%)
COVID127 Interactome_Stukalov_A549_72h_ORF8 29 Interactome A549 ORF8 72h Significance defined by Supp Table. Features sorted by pvalue. 18 (62%) 25 (86%)
COVID128 Interactome_Stukalov_A549_72h_ORF9B 2 Interactome A549 ORF9B 72h Significance defined by Supp Table. Features sorted by pvalue. 1 (50%) 2 (100%)
COVID129 Interactome_Stukalov_A549_72h_S 2 Interactome A549 S 72h Significance defined by Supp Table. Features sorted by pvalue. 1 (50%) 2 (100%)
COVID130 Phosphoproteome_Stukalov_A549-ACE2_24h_Down 300 Phosphoproteome A549-ACE2 SARS-CoV-2 Mock 24h Significance defined by Supp Table. Features sorted by pvalue. 168 (56%) 237 (79%)
COVID131 Phosphoproteome_Stukalov_A549-ACE2_24h_Up 300 Phosphoproteome A549-ACE2 SARS-CoV-2 Mock 24h Significance defined by Supp Table. Features sorted by pvalue. 190 (63%) 244 (81%)
COVID132 Phosphoproteome_Stukalov_A549-ACE2_6h_Down 69 Phosphoproteome A549-ACE2 SARS-CoV-2 Mock 6h Significance defined by Supp Table. Features sorted by pvalue. 51 (74%) 64 (93%)
COVID133 Phosphoproteome_Stukalov_A549-ACE2_6h_Up 69 Phosphoproteome A549-ACE2 SARS-CoV-2 Mock 6h Significance defined by Supp Table. Features sorted by pvalue. 43 (62%) 61 (88%)
COVID134 Proteome_Stukalov_A549-ACE2_24h_Down 299 Proteome A549-ACE2 SARS-CoV-2 Mock 24h Significance defined by Supp Table. Features sorted by pvalue. 177 (59%) 227 (76%)
COVID135 Proteome_Stukalov_A549-ACE2_24h_Up 131 Proteome A549-ACE2 SARS-CoV-2 Mock 24h Significance defined by Supp Table. Features sorted by pvalue. 92 (70%) 105 (80%)
COVID136 Proteome_Stukalov_A549-ACE2_6h_Down 10 Proteome A549-ACE2 SARS-CoV-2 Mock 6h Significance defined by Supp Table. Features sorted by pvalue. 9 (90%) 9 (90%)
COVID137 Proteome_Stukalov_A549-ACE2_6h_Up 8 Proteome A549-ACE2 SARS-CoV-2 Mock 6h Significance defined by Supp Table. Features sorted by pvalue. 8 (100%) 5 (62%)
COVID138 Proteome_Stukalov_A549_72h_E_Down 238 Proteome A549 E Control 72h Significance defined by Supp Table. Features sorted by pvalue. 203 (85%) 154 (65%)
COVID139 Proteome_Stukalov_A549_72h_E_Up 186 Proteome A549 E Control 72h Significance defined by Supp Table. Features sorted by pvalue. 143 (77%) 126 (68%)
COVID140 Proteome_Stukalov_A549_72h_M_Down 168 Proteome A549 M Control 72h Significance defined by Supp Table. Features sorted by pvalue. 142 (85%) 99 (59%)
COVID141 Proteome_Stukalov_A549_72h_M_Up 103 Proteome A549 M Control 72h Significance defined by Supp Table. Features sorted by pvalue. 82 (80%) 80 (78%)
COVID142 Proteome_Stukalov_A549_72h_NSP10_Down 32 Proteome A549 NSP10 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 26 (81%) 19 (59%)
COVID143 Proteome_Stukalov_A549_72h_NSP10_Up 49 Proteome A549 NSP10 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 39 (80%) 37 (76%)
COVID144 Proteome_Stukalov_A549_72h_NSP12_Down 210 Proteome A549 NSP12 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 145 (69%) 129 (61%)
COVID145 Proteome_Stukalov_A549_72h_NSP12_Up 40 Proteome A549 NSP12 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 31 (78%) 18 (45%)
COVID146 Proteome_Stukalov_A549_72h_NSP13_Down 97 Proteome A549 NSP13 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 58 (60%) 77 (79%)
COVID147 Proteome_Stukalov_A549_72h_NSP13_Up 120 Proteome A549 NSP13 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 95 (79%) 79 (66%)
COVID148 Proteome_Stukalov_A549_72h_NSP14_Down 39 Proteome A549 NSP14 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 30 (77%) 28 (72%)
COVID149 Proteome_Stukalov_A549_72h_NSP14_Up 45 Proteome A549 NSP14 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 32 (71%) 35 (78%)
COVID150 Proteome_Stukalov_A549_72h_NSP15_Down 34 Proteome A549 NSP15 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 29 (85%) 21 (62%)
COVID151 Proteome_Stukalov_A549_72h_NSP15_Up 69 Proteome A549 NSP15 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 56 (81%) 48 (70%)
COVID152 Proteome_Stukalov_A549_72h_NSP16_Down 39 Proteome A549 NSP16 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 36 (92%) 26 (67%)
COVID153 Proteome_Stukalov_A549_72h_NSP16_Up 65 Proteome A549 NSP16 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 54 (83%) 41 (63%)
COVID154 Proteome_Stukalov_A549_72h_NSP1_Down 214 Proteome A549 NSP1 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 128 (60%) 127 (59%)
COVID155 Proteome_Stukalov_A549_72h_NSP1_Up 128 Proteome A549 NSP1 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 83 (65%) 80 (62%)
COVID156 Proteome_Stukalov_A549_72h_NSP2_Down 121 Proteome A549 NSP2 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 87 (72%) 80 (66%)
COVID157 Proteome_Stukalov_A549_72h_NSP2_Up 69 Proteome A549 NSP2 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 47 (68%) 44 (64%)
COVID158 Proteome_Stukalov_A549_72h_NSP3_MACROD_Down 48 Proteome A549 NSP3_MACROD Control 72h Significance defined by Supp Table. Features sorted by pvalue. 38 (79%) 35 (73%)
COVID159 Proteome_Stukalov_A549_72h_NSP3_MACROD_Up 79 Proteome A549 NSP3_MACROD Control 72h Significance defined by Supp Table. Features sorted by pvalue. 53 (67%) 57 (72%)
COVID160 Proteome_Stukalov_A549_72h_NSP4_Down 41 Proteome A549 NSP4 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 31 (76%) 28 (68%)
COVID161 Proteome_Stukalov_A549_72h_NSP4_Up 82 Proteome A549 NSP4 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 56 (68%) 52 (63%)
COVID162 Proteome_Stukalov_A549_72h_NSP6_Down 68 Proteome A549 NSP6 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 52 (76%) 41 (60%)
COVID163 Proteome_Stukalov_A549_72h_NSP6_Up 64 Proteome A549 NSP6 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 44 (69%) 39 (61%)
COVID164 Proteome_Stukalov_A549_72h_NSP7_Down 34 Proteome A549 NSP7 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 26 (76%) 22 (65%)
COVID165 Proteome_Stukalov_A549_72h_NSP7_Up 39 Proteome A549 NSP7 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 23 (59%) 26 (67%)
COVID166 Proteome_Stukalov_A549_72h_NSP8_Down 60 Proteome A549 NSP8 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 46 (77%) 43 (72%)
COVID167 Proteome_Stukalov_A549_72h_NSP8_Up 52 Proteome A549 NSP8 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 40 (77%) 32 (62%)
COVID168 Proteome_Stukalov_A549_72h_NSP9_Down 42 Proteome A549 NSP9 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 35 (83%) 26 (62%)
COVID169 Proteome_Stukalov_A549_72h_NSP9_Up 55 Proteome A549 NSP9 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 47 (85%) 36 (65%)
COVID170 Proteome_Stukalov_A549_72h_N_Down 137 Proteome A549 N Control 72h Significance defined by Supp Table. Features sorted by pvalue. 114 (83%) 97 (71%)
COVID171 Proteome_Stukalov_A549_72h_N_Up 103 Proteome A549 N Control 72h Significance defined by Supp Table. Features sorted by pvalue. 83 (81%) 70 (68%)
COVID172 Proteome_Stukalov_A549_72h_ORF3_Down 300 Proteome A549 ORF3 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 209 (70%) 207 (69%)
COVID173 Proteome_Stukalov_A549_72h_ORF3_Up 291 Proteome A549 ORF3 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 203 (70%) 214 (74%)
COVID174 Proteome_Stukalov_A549_72h_ORF6_Down 79 Proteome A549 ORF6 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 64 (81%) 56 (71%)
COVID175 Proteome_Stukalov_A549_72h_ORF6_Up 90 Proteome A549 ORF6 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 62 (69%) 55 (61%)
COVID176 Proteome_Stukalov_A549_72h_ORF7A_Down 67 Proteome A549 ORF7A Control 72h Significance defined by Supp Table. Features sorted by pvalue. 54 (81%) 47 (70%)
COVID177 Proteome_Stukalov_A549_72h_ORF7A_Up 74 Proteome A549 ORF7A Control 72h Significance defined by Supp Table. Features sorted by pvalue. 56 (76%) 47 (64%)
COVID178 Proteome_Stukalov_A549_72h_ORF7B_Down 123 Proteome A549 ORF7B Control 72h Significance defined by Supp Table. Features sorted by pvalue. 95 (77%) 82 (67%)
COVID179 Proteome_Stukalov_A549_72h_ORF7B_Up 130 Proteome A549 ORF7B Control 72h Significance defined by Supp Table. Features sorted by pvalue. 96 (74%) 92 (71%)
COVID180 Proteome_Stukalov_A549_72h_ORF8_Down 62 Proteome A549 ORF8 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 44 (71%) 39 (63%)
COVID181 Proteome_Stukalov_A549_72h_ORF8_Up 79 Proteome A549 ORF8 Control 72h Significance defined by Supp Table. Features sorted by pvalue. 49 (62%) 53 (67%)
COVID182 Proteome_Stukalov_A549_72h_ORF9B_Down 218 Proteome A549 ORF9B Control 72h Significance defined by Supp Table. Features sorted by pvalue. 116 (53%) 134 (61%)
COVID183 Proteome_Stukalov_A549_72h_ORF9B_Up 116 Proteome A549 ORF9B Control 72h Significance defined by Supp Table. Features sorted by pvalue. 68 (59%) 78 (67%)
COVID184 Proteome_Stukalov_A549_72h_S_Down 48 Proteome A549 S Control 72h Significance defined by Supp Table. Features sorted by pvalue. 36 (75%) 29 (60%)
COVID185 Proteome_Stukalov_A549_72h_S_Up 64 Proteome A549 S Control 72h Significance defined by Supp Table. Features sorted by pvalue. 47 (73%) 41 (64%)
COVID186 RNA_Stukalov_A549-ACE2_12h_Down 18 RNA-seq A549-ACE2 SARS-CoV-2 Mock 12h Significance defined by Supp Table. Features sorted by pvalue. 17 (94%) 13 (72%)
COVID187 RNA_Stukalov_A549-ACE2_12h_Up 13 RNA-seq A549-ACE2 SARS-CoV-2 Mock 12h Significance defined by Supp Table. Features sorted by pvalue. 10 (77%) 11 (85%)
COVID188 RNA_Stukalov_A549-ACE2_18h_Down 32 RNA-seq A549-ACE2 SARS-CoV-2 Mock 18h Significance defined by Supp Table. Features sorted by pvalue. 26 (81%) 15 (47%)
COVID189 RNA_Stukalov_A549-ACE2_18h_Up 66 RNA-seq A549-ACE2 SARS-CoV-2 Mock 18h Significance defined by Supp Table. Features sorted by pvalue. 54 (82%) 61 (92%)
COVID190 RNA_Stukalov_A549-ACE2_24h_Down 38 RNA-seq A549-ACE2 SARS-CoV-2 Mock 24h Significance defined by Supp Table. Features sorted by pvalue. 25 (66%) 26 (68%)
COVID191 RNA_Stukalov_A549-ACE2_24h_Up 98 RNA-seq A549-ACE2 SARS-CoV-2 Mock 24h Significance defined by Supp Table. Features sorted by pvalue. 82 (84%) 84 (86%)
COVID192 RNA_Stukalov_A549-ACE2_30h_Down 97 RNA-seq A549-ACE2 SARS-CoV-2 Mock 30h Significance defined by Supp Table. Features sorted by pvalue. 46 (47%) 60 (62%)
COVID193 RNA_Stukalov_A549-ACE2_30h_Up 300 RNA-seq A549-ACE2 SARS-CoV-2 Mock 30h Significance defined by Supp Table. Features sorted by pvalue. 163 (54%) 237 (79%)
COVID194 RNA_Stukalov_A549-ACE2_3h_Down 2 RNA-seq A549-ACE2 SARS-CoV-2 Mock 3h Significance defined by Supp Table. Features sorted by pvalue. 2 (100%) 1 (50%)
COVID195 RNA_Stukalov_A549-ACE2_3h_Up 16 RNA-seq A549-ACE2 SARS-CoV-2 Mock 3h Significance defined by Supp Table. Features sorted by pvalue. 8 (50%) 15 (94%)
COVID196 RNA_Stukalov_A549-ACE2_6h_Down 15 RNA-seq A549-ACE2 SARS-CoV-2 Mock 6h Significance defined by Supp Table. Features sorted by pvalue. 14 (93%) 10 (67%)
COVID197 RNA_Stukalov_A549-ACE2_6h_Up 6 RNA-seq A549-ACE2 SARS-CoV-2 Mock 6h Significance defined by Supp Table. Features sorted by pvalue. 6 (100%) 6 (100%)
COVID198 Ubiquitinome_Stukalov_A549-ACE2_24h_Down 196 Ubiquitinome A549-ACE2 SARS-CoV-2 Mock 24h Significance defined by Supp Table. Features sorted by pvalue. 142 (72%) 147 (75%)
COVID199 Ubiquitinome_Stukalov_A549-ACE2_24h_Up 300 Ubiquitinome A549-ACE2 SARS-CoV-2 Mock 24h Significance defined by Supp Table. Features sorted by pvalue. 197 (66%) 242 (81%)
COVID200 Ubiquitinome_Stukalov_A549-ACE2_6h_Down 250 Ubiquitinome A549-ACE2 SARS-CoV-2 Mock 6h Significance defined by Supp Table. Features sorted by pvalue. 167 (67%) 185 (74%)
COVID201 Ubiquitinome_Stukalov_A549-ACE2_6h_Up 100 Ubiquitinome A549-ACE2 SARS-CoV-2 Mock 6h Significance defined by Supp Table. Features sorted by pvalue. 79 (79%) 76 (76%)

19. Vanderheiden et al. Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures bioRxiv pre-print

 IsOMICS Transcriptomics,  SampleType in vitro,  CellType pHAE cultures,  VirusStrain SARS-CoV-2, 2019-nCoV/WA1,  Timepoints 48 h,  Perturbations ,  HasCompleteData Yes,  GeneListSource Processed from GEO read counts.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined344       234 (68%)
COVID202 RNA_Vanderheiden_pHAE_48h_Down 189 RNA-seq pHAE SARS-CoV-2 Mock 48h Significance defined by Log2FC >= 1.0 and adjusted p-value < 0.01. Features sorted by pvalue. 0 (0%) 124 (66%)
COVID203 RNA_Vanderheiden_pHAE_48h_Up 155 RNA-seq pHAE SARS-CoV-2 Mock 48h Significance defined by Log2FC >= 1.0 and adjusted p-value < 0.01. Features sorted by pvalue. 0 (0%) 110 (71%)

20. Appelberg et al. Dysregulation in mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells biorxiv pre-print
SARS-CoV2 infection in Huh7 cell line and performed transcriptomics and proteomics analysis in uninfected and 24,48,72 hours post infection to identify the host cellular response against SARS-CoV2.

 IsOMICS RNA-Seq, proteomics,  SampleType in vitro,  CellType Huh-7,  VirusStrain SARS-CoV-2,  Timepoints 24, 48, 72 h,  Perturbations ,  HasCompleteData Yes,  GeneListSource Processed from raw reads.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined629       411 (65%)
COVID001 RNA_Appelberg_Huh-7_24h_Down 6 RNA-seq Huh-7 SARS-CoV-2 uninfected 24h 2 (33%) 4 (67%)
COVID002 RNA_Appelberg_Huh-7_24h_Up 8 RNA-seq Huh-7 SARS-CoV-2 uninfected 24h 2 (25%) 7 (88%)
COVID003 RNA_Appelberg_Huh-7_48h_Down 23 RNA-seq Huh-7 SARS-CoV-2 uninfected 48h 17 (74%) 17 (74%)
COVID004 RNA_Appelberg_Huh-7_48h_Up 95 RNA-seq Huh-7 SARS-CoV-2 uninfected 48h 83 (87%) 40 (42%)
COVID005 RNA_Appelberg_Huh-7_72h_Down 300 RNA-seq Huh-7 SARS-CoV-2 uninfected 72h 16 (5%) 237 (79%)
COVID006 RNA_Appelberg_Huh-7_72h_Up 300 RNA-seq Huh-7 SARS-CoV-2 uninfected 72h 84 (28%) 158 (53%)

21. Keller et al. Gene expression in CD21low and CD21pos B cells from CVID patients GEO data only
Gene expression in CD21low and CD21pos B cells from CVID patients.

 IsOMICS RNA-Seq,  SampleType patient samples,  CellType B cells,  VirusStrain SARS-CoV-2,  Timepoints N/A,  Perturbations ,  HasCompleteData Yes,  GeneListSource GEO read counts.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined780       493 (63%)
COVID021 RNA_Keller_B-cells-CD21pos_infection_Down 23 RNA-seq B cells SARS-CoV-2 (CD21+) uninfected (CD21+) 4 (17%) 17 (74%)
COVID022 RNA_Keller_B-cells-CD21pos_infection_Up 269 RNA-seq B cells SARS-CoV-2 (CD21+) uninfected (CD21+) 86 (32%) 172 (64%)
COVID023 RNA_Keller_B-cells-Infected_CD21pos_Down 278 RNA-seq B cells SARS-CoV-2 (CD21+) SARS-CoV-2 (CD21 low) 80 (29%) 185 (67%)
COVID024 RNA_Keller_B-cells-Infected_CD21pos_Up 300 RNA-seq B cells SARS-CoV-2 (CD21+) SARS-CoV-2 (CD21 low) 10 (3%) 175 (58%)

22. Liao et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing medRxiv pre-print

 IsOMICS scRNA-seq, TCR-seq,  SampleType patient samples,  CellType BALF,  VirusStrain SARS-CoV-2,  Timepoints n/a,  Perturbations ,  HasCompleteData yes,  GeneListSource GEO read counts.

COVID IDList NameSizeTechnologySourceTreatmentReferenceTimePointsComments#Found Multiple Times#Found in Other Studies
 Combined1382       813 (59%)
COVID029 RNA_Liao_BALF-mild_Down 300 RNA-seq BALF SARS-CoV-2 (mild) uninfected 120 (40%) 181 (60%)
COVID030 RNA_Liao_BALF-mild_Up 300 RNA-seq BALF SARS-CoV-2 (mild) uninfected 102 (34%) 133 (44%)
COVID031 RNA_Liao_BALF-severe_Down 300 RNA-seq BALF SARS-CoV-2 (severe) uninfected 231 (77%) 150 (50%)
COVID032 RNA_Liao_BALF-severe_Up 300 RNA-seq BALF SARS-CoV-2 (severe) uninfected 153 (51%) 254 (85%)
COVID033 RNA_Liao_BALF-severe-vs-mild_Down 300 RNA-seq BALF SARS-CoV-2 (severe) SARS-CoV-2 (mild) 140 (47%) 117 (39%)
COVID034 RNA_Liao_BALF-severe-vs-mild_Up 300 RNA-seq BALF SARS-CoV-2 (severe) SARS-CoV-2 (mild) 74 (25%) 230 (77%)